Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Human Cytomegalovirus Immune Globulin · Cytogam

Plasma-derived product · Immune activation, directed at cytomegalovirus · developed by Kamada

Approved FDA, Apr 1990
KMDA Developer
1 Registered trials

What is Human Cytomegalovirus Immune Globulin?

Human Cytomegalovirus Immune Globulin is a sterilized solution of immunoglobulins against cytomegalovirus (CMV), derived from human plasma of CMV-infected donors. It is used for passive immunization to help prevent or treat CMV infection and is studied in CMV infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Cytogam
Drug type
Plasma-derived product
Targets
cytomegalovirus
Mechanism
Immune activation, directed at cytomegalovirus
Pathways
passive immunization
Therapy area
Infectious disease
Developer
Kamada Ltd. (KMDA)
FDA status
Approved as Cytogam (April 17, 1990), BLA103189
UNII
129L90A25N

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07009548 Phase 4 Cytomegalovirus (CMV) Infection Enrolling by invitation KMDA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cytomegalovirus (CMV) Infection

More from Kamada

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KMDA page.

Follow KMDA, the company behind Human Cytomegalovirus Immune Globulin

See KMDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KMDA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.